Sunscreen: How to Help Protect Your Skin From the Sun

Why It Matters

Stronger FDA standards protect consumers from ineffective or unsafe sunscreens and force manufacturers to meet higher efficacy benchmarks, shaping the U.S. sun‑care market.

Key Takeaways

• FDA proposed new sunscreen safety rules in 2021 under CARES Act
• Broad‑spectrum SPF 15+ recommended; reapply every two hours
• Infants under six months should avoid sunscreen; use clothing protection
• Expired or recalled sunscreens may pose health risks; check labels

Pulse Analysis

The FDA’s renewed focus on sunscreen regulation reflects a broader public‑health push to curb skin‑cancer rates. By leveraging the CARES Act authority, the agency is moving toward a rulemaking process that could require more rigorous testing of active ingredients, clearer labeling of SPF and water‑resistance claims, and tighter controls on product stability. Manufacturers that adapt early will avoid costly reformulations and gain a competitive edge as consumers gravitate toward compliant, science‑backed options.

For consumers, the practical takeaways are straightforward yet often overlooked. Broad‑spectrum sunscreens with an SPF of at least 15 should be applied liberally—about one ounce for full‑body coverage—and reapplied every two hours, especially after swimming or sweating. Infants under six months are best protected with clothing and shade rather than topical agents, while older children can safely use FDA‑approved products. Awareness of expiration dates, recall notices, and flammable spray formulations further safeguards health and ensures the product performs as advertised.

Industry analysts see the regulatory tightening as a catalyst for innovation. Companies are investing in mineral‑based filters like zinc oxide and titanium dioxide, which face fewer absorption concerns than some organic filters. Global differences in classification—cosmetics abroad versus drugs in the U.S.—create opportunities for cross‑border product strategies, but also demand meticulous label translation. As the FDA finalizes its rules, brands that prioritize transparent ingredient disclosure and robust testing are likely to capture market share, while laggards risk recalls and lost consumer trust.